<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="874">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360980</url>
  </required_header>
  <id_info>
    <org_study_id>SBMU.IR.REC.165423</org_study_id>
    <nct_id>NCT04360980</nct_id>
  </id_info>
  <brief_title>The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection</brief_title>
  <official_title>Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on data regarding the effect of colchicine on the modulation of immune system and
      decreasing cytokine release and inflammation the question arises whether colchicine,
      administered in a relatively low dose, could potentially have an effect on COVID-19
      Polymerase chain reaction(PCR) positive patients .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80 Patients with positive nasopharyngeal swab PCR for COVID-19 which were not hypoxic but
      showed computed tomography involvement compatible with COVID-19 admitted in ward (not in
      Intensive care unit) included and randomized in to two groups. All patients received standard
      treatment protocol including essential minerals, vitamins as antioxidants, antibiotics and
      Kaletra while in one randomly assigned group colchicine would be added.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CRPxN/R ratio change</measure>
    <time_frame>2 weeks</time_frame>
    <description>increasing inflammatory status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical deterioration by the WHO definition</measure>
    <time_frame>2 weeks</time_frame>
    <description>including change in fever or O2 Saturation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PCR Viral Load</measure>
    <time_frame>2 weeks</time_frame>
    <description>change in RT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT severity involvement index</measure>
    <time_frame>2weeks</time_frame>
    <description>change in CT involvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDH change</measure>
    <time_frame>2 weeks</time_frame>
    <description>change in LDH</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 RT-PCR positive COVID-19 patients without hypoxemia administered Colchicine plus standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>40 RT-PCR positive COVID-19 patients without hypoxemia receiving vitamin C 3grams daily , 400 mg Tiamine, Selenium , Omega-3 500 mg daily, Vit A , Vit D, Azithromycine, Ceftriaxone, Kaletra 400 BID 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine Tablets</intervention_name>
    <description>1.5 mg loading then 0.5 mg BID P.O</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Colchicine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years old with nasopharyngeal swab confirmed COVID-19 PCR, CT involvement
             compatible with COVID, Fever and Dyspnea without hypoxemia.

        Exclusion Criteria:

          -  Patient who is not willing to enter in study

          -  Known hypersensitivity to colchicine

          -  Hepatic failure

          -  Renal failure with eGFR&lt;20 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SBMU</last_name>
    <role>Principal Investigator</role>
    <affiliation>CKDRC,SBMU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CKDRC,SBMU, MD</last_name>
    <phone>00989122404331</phone>
    <email>nooshindalili4@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SBMU</name>
      <address>
        <city>Tehran</city>
        <zip>1666664321</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nooshin Dalili, MD</last_name>
      <phone>00989122404331</phone>
      <email>nooshindalili4@gmail.com</email>
    </contact>
    <contact_backup>
      <email>nooshindalili4@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nooshin Dalili</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nooshin Dalili, Dr</last_name>
      <phone>00989122404331</phone>
      <email>nooshindalili4@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>nooshin dalili</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

